[go: up one dir, main page]

PE20141568A1 - Anticuerpos humanizados que reconocen la alfa-sinucleina - Google Patents

Anticuerpos humanizados que reconocen la alfa-sinucleina

Info

Publication number
PE20141568A1
PE20141568A1 PE2014000613A PE2014000613A PE20141568A1 PE 20141568 A1 PE20141568 A1 PE 20141568A1 PE 2014000613 A PE2014000613 A PE 2014000613A PE 2014000613 A PE2014000613 A PE 2014000613A PE 20141568 A1 PE20141568 A1 PE 20141568A1
Authority
PE
Peru
Prior art keywords
sinuclein
seq
humanized antibodies
recognize alpha
refers
Prior art date
Application number
PE2014000613A
Other languages
English (en)
Inventor
Jose Saldanha
Tarlochan S Nijjar
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of PE20141568A1 publication Critical patent/PE20141568A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ANTICUERPO QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA MADURA QUE COMPRENDE LAS TRES CDRS DE KABAT DE LA SEQ ID NO:11, Y SIENDO EL 90% IDENTICA A LA SEQ ID NO: 11, Y UNA CADENA LIGERA QUE COMPRENDE LAS TRES CDRS DE KABAT DE LA SEQ ID NO: 4, Y SIENDO EL 90% IDENTICA A LA SEQ ID NO: 4. DICHOS ANTICUERPOS SE UNEN A LA ALFA SINUCLEINA HUMANA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA LA INMUNOTERAPIA DE LA ENFERMEDAD DE CUERPOS DE LEWY.
PE2014000613A 2011-10-28 2012-10-26 Anticuerpos humanizados que reconocen la alfa-sinucleina PE20141568A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553131P 2011-10-28 2011-10-28
US201261711208P 2012-10-08 2012-10-08

Publications (1)

Publication Number Publication Date
PE20141568A1 true PE20141568A1 (es) 2014-11-21

Family

ID=48168610

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000613A PE20141568A1 (es) 2011-10-28 2012-10-26 Anticuerpos humanizados que reconocen la alfa-sinucleina

Country Status (33)

Country Link
US (7) US8609820B2 (es)
EP (2) EP3378535B1 (es)
JP (4) JP5775974B2 (es)
KR (1) KR101600733B1 (es)
CN (2) CN107880123A (es)
AU (3) AU2012328530A1 (es)
BR (1) BR112014010198B1 (es)
CA (1) CA2853531C (es)
CL (1) CL2014001073A1 (es)
CO (1) CO7020875A2 (es)
CY (1) CY1120398T1 (es)
DK (2) DK3378535T5 (es)
ES (2) ES2669395T3 (es)
FI (1) FI3378535T3 (es)
HK (1) HK1252895A1 (es)
HR (2) HRP20180728T1 (es)
HU (2) HUE061978T2 (es)
IL (2) IL232264B (es)
LT (2) LT2771031T (es)
MX (2) MX370234B (es)
MY (1) MY165038A (es)
PE (1) PE20141568A1 (es)
PH (1) PH12014500938B1 (es)
PL (2) PL2771031T3 (es)
PT (2) PT3378535T (es)
RS (2) RS63930B1 (es)
RU (1) RU2743738C2 (es)
SG (1) SG11201401857WA (es)
SI (2) SI3378535T1 (es)
SM (2) SMT201800307T1 (es)
UA (1) UA116194C2 (es)
WO (1) WO2013063516A1 (es)
ZA (1) ZA201403864B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US11191832B2 (en) * 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
ES2903402T3 (es) 2016-06-02 2022-04-01 Medimmune Ltd Anticuerpos contra alfa-sinuclueína y usos de los mismos
US20180328943A1 (en) * 2016-09-30 2018-11-15 Enzo Biochem, Inc. Immunomodulatory compositions and methods of use thereof
JP7217229B2 (ja) * 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
JP2020501132A (ja) 2016-12-02 2020-01-16 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインの二次構造プロファイルを検出する赤外線アッセイ
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110494445B (zh) 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
WO2018151821A1 (en) * 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
CA3085572A1 (en) * 2017-12-14 2019-06-20 Abl Bio Inc. Bispecific antibody to a-syn/igf1r and use thereof
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
EP3833435B1 (en) 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
EP3985022A4 (en) * 2019-06-14 2023-08-02 ABL Bio, Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
CN112710850A (zh) * 2020-12-29 2021-04-27 苏州百志生物科技有限公司 一种检测人体液中α-突触核蛋白含量的试剂盒
CN113912712B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE60036082T2 (de) 1999-02-05 2008-06-12 Samsung Electronics Co., Ltd., Suwon Verfahren und vorrichtung zur wiederauffindung von texturbildern
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1531864A4 (en) 2002-05-13 2006-08-23 Alexion Pharma Inc HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
EP1589033A4 (en) * 2003-01-22 2006-04-12 Takeda Pharmaceutical ANTIBODY AND ITS USE
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7022550B2 (en) 2004-04-07 2006-04-04 Gelcore Llc Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
AR054428A1 (es) 2005-03-08 2007-06-27 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
AU2006329963B2 (en) 2005-12-06 2011-06-09 Amgen Inc. Polishing steps used in multi-step protein purification processes
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
PT2126093E (pt) 2007-03-02 2012-12-03 Boehringer Ingelheim Pharma Melhoramento da produção de proteínas
RS53402B (sr) * 2007-03-22 2014-10-31 Genentech, Inc. Vezivanje apoptotskih anti-ige antitela za membranski ige
CA2681743A1 (en) 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
CN102016059B (zh) 2007-12-28 2014-10-22 依兰制药公司 淀粉样变性的治疗和预防
EP2282758B1 (en) * 2008-04-29 2018-11-21 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
JP5810413B2 (ja) * 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
MX379016B (es) 2009-07-28 2025-03-10 Takeda Pharmaceuticals Co Composiciones y metodos para tratar enfermedad de gaucher.
PL214940B1 (pl) 2009-07-31 2013-09-30 Lozano Platonoff Alberto Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011090720A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP6158511B2 (ja) 2010-06-11 2017-07-05 協和発酵キリン株式会社 抗ｔｉｍ−３抗体
SI2593128T1 (en) 2010-07-15 2018-08-31 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
MX344268B (es) 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
WO2012109280A2 (en) 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
US8619359B2 (en) 2011-04-27 2013-12-31 Howard Letovsky Electronic microscope filter
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
CN103764166B (zh) 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
MX391043B (es) 2011-10-25 2025-03-21 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
CA3078979C (en) 2011-10-31 2022-10-11 Genentech, Inc. Formulation comprising an anti-il13 antibody having extended stability
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
HK1205521A1 (en) 2012-08-29 2015-12-18 霍夫曼-拉罗奇有限公司 Blood brain barrier shuttle
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
ES2669395T3 (es) 2018-05-25
PH12014500938A1 (en) 2014-06-30
IL232264B (en) 2020-02-27
RS63930B1 (sr) 2023-02-28
CO7020875A2 (es) 2014-08-11
AU2016202622B2 (en) 2017-09-14
CN107880123A (zh) 2018-04-06
US20200024336A1 (en) 2020-01-23
RU2016101137A (ru) 2018-11-16
FI3378535T3 (fi) 2023-04-12
WO2013063516A1 (en) 2013-05-02
CA2853531C (en) 2020-03-10
CY1120398T1 (el) 2019-07-10
BR112014010198B1 (pt) 2022-12-06
US10723792B2 (en) 2020-07-28
US9884906B2 (en) 2018-02-06
DK2771031T3 (en) 2018-05-28
DK3378535T5 (da) 2024-09-30
LT2771031T (lt) 2018-08-27
SMT202300048T1 (it) 2023-03-17
HK1252895A1 (zh) 2019-06-06
AU2016202622A1 (en) 2016-05-19
JP5775974B2 (ja) 2015-09-09
NZ625624A (en) 2016-06-24
PL2771031T3 (pl) 2018-09-28
CA2853531A1 (en) 2013-05-02
LT3378535T (lt) 2023-02-27
RU2014121325A (ru) 2015-12-10
IL272615A (en) 2020-03-31
SI3378535T1 (sl) 2023-04-28
SG11201401857WA (en) 2014-09-26
MX2014005038A (es) 2015-03-09
JP6592059B2 (ja) 2019-10-16
HRP20180728T1 (hr) 2018-07-27
JP2016208981A (ja) 2016-12-15
AU2017276296B2 (en) 2020-01-16
RS57315B1 (sr) 2018-08-31
BR112014010198A2 (pt) 2018-08-07
US12528858B2 (en) 2026-01-20
PH12014500938B1 (en) 2019-01-16
IL232264A0 (en) 2014-06-30
US10450369B2 (en) 2019-10-22
US20170240621A1 (en) 2017-08-24
EP2771031A1 (en) 2014-09-03
PT2771031T (pt) 2018-05-24
US20130108546A1 (en) 2013-05-02
CN104334184B (zh) 2017-12-29
JP5960328B2 (ja) 2016-08-02
ZA201403864B (en) 2015-08-26
MX2019014658A (es) 2020-02-07
US20210040188A1 (en) 2021-02-11
JP2015232002A (ja) 2015-12-24
DK3378535T3 (da) 2023-01-30
JP6234511B2 (ja) 2017-11-22
CN104334184A (zh) 2015-02-04
EP2771031A4 (en) 2015-03-18
US20140275495A1 (en) 2014-09-18
HRP20230065T1 (hr) 2023-03-03
US8609820B2 (en) 2013-12-17
EP3378535B1 (en) 2023-01-04
KR101600733B1 (ko) 2016-03-09
KR20140081898A (ko) 2014-07-01
US20180201669A1 (en) 2018-07-19
SMT201800307T1 (it) 2018-09-13
PT3378535T (pt) 2023-02-06
HUE037811T2 (hu) 2018-09-28
JP2018046836A (ja) 2018-03-29
MX370234B (es) 2019-12-06
CL2014001073A1 (es) 2014-12-19
HK1201450A1 (en) 2015-09-04
RU2743738C2 (ru) 2021-02-25
IL272615B (en) 2022-04-01
US9556259B2 (en) 2017-01-31
MY165038A (en) 2018-02-28
SI2771031T1 (en) 2018-08-31
EP3378535A1 (en) 2018-09-26
JP2015502341A (ja) 2015-01-22
ES2937409T3 (es) 2023-03-28
US20220411486A1 (en) 2022-12-29
RU2016101137A3 (es) 2020-01-09
HUE061978T2 (hu) 2023-09-28
AU2012328530A1 (en) 2014-06-26
UA116194C2 (uk) 2018-02-26
PL3378535T3 (pl) 2023-05-08
AU2017276296A1 (en) 2018-01-18
US11345749B2 (en) 2022-05-31
HK1206637A1 (en) 2016-01-15
EP2771031B1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
PE20141568A1 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20140247A1 (es) Anticuerpos anti-cd38
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20141017A1 (es) Anticuerpos del cea
PE20190208A1 (es) Anticuerpos que reconocen tau
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
AR084315A1 (es) Anticuerpos anti-notch1
PE20081478A1 (es) Anticuerpos cd44
MX338758B (es) Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
PE20190261A1 (es) Anticuerpos que reconocen tau
AR109715A1 (es) Anticuerpos anti-cd27
PE20131209A1 (es) Anticuerpos anti-fap
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
PE20142407A1 (es) Formulacion de anticuerpos
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph

Legal Events

Date Code Title Description
FC Refusal